1 / 25

Vitamin D and cancer

Vitamin D and cancer. 1000,000,000 people around the world. multi-system involvement. Vitamin D physiology. http://www.precisionnutrition.com/wordpress/wp-content/uploads/2009/06/vitamin-d-metabolism.gif. vit . D physiology. http://www.nejm.org/doi/pdf/10.1056/NEJMra070553.

joey
Download Presentation

Vitamin D and cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Vitamin D and cancer

  2. 1000,000,000 people around the world. • multi-system involvement.

  3. Vitamin D physiology..

  4. http://www.precisionnutrition.com/wordpress/wp-content/uploads/2009/06/vitamin-d-metabolism.gifhttp://www.precisionnutrition.com/wordpress/wp-content/uploads/2009/06/vitamin-d-metabolism.gif

  5. vit. D physiology http://www.nejm.org/doi/pdf/10.1056/NEJMra070553

  6. Multi-system..but What about vit. D and cancer..??!!

  7. Evidence: • 1- pre-clinical. • 2- clinical.

  8. 1. Pre-clinical • Action on : 1- Cell ploferation. 2- Apoptosis. 3- Angiogenesis. 4- Inflamation.

  9. 1- Cell proleferation : • increase CDR-inhibetors • up-regulate IGFBP3 • -M.J. Campbell, E. Elstner, S. Holden, M. Uskokovic, H.P. Koeffler, J. Mol. Endocrinol. 19 (1997) 15–27. • E.S. Yang, K.L. Burnstein, J. Biol. Chem. 278 (2003) 46862–46868. • B.J. Boyle, X.Y. Zhao, P. Cohen, D. Feldman, J. Urol. 165 (2001) 1319–1324. • L. Peng, P.J. Malloy, D. Feldman, Mol. Endocrinol. 18 (2004) 1109–1119.534

  10. 2- Apoptosis : expression of P73 expression of Bcl-2 gene telomere activity autophagy the pro-apoptotic effect when administerwith new anti-cancer medication (tricostatin A) -Y. Ma, W.D. Yu, P.A. Hershberger, G. Flynn, R.X. Kong, D.L. Trump, C.S. Johnson, Mol. Cancer Ther. 7 (2008) 3047–3055. -S.E. Blutt, T.J. McDonnell, T.C. Polek, N.L. Weigel, Endocrinology 141 (2000) 10–17. -M. Hoyer-Hansen, S.P. Nordbrandt, M. Jaattela, Trends Mol. Med. 16 (2010) 295–302. -L. Pan, A.F. Matloob, J. Du, H. Pan, Z. Dong, J. Zhao, Y. Feng, Y. Zhong, B. Huang, J. Lu, FEBS J. 277 (2010) 989–999.

  11. 3- Angiogenesis: expression of Tenascin-C, alpha-6 & beta-4. VEGF, IL-8 & COX-2. expressio of E-cadherin. • M.J. Campbell, E. Elstner, S. Holden, M. Uskokovic, H.P. Koeffler, J. Mol. Endocrinol. 19 (1997) 15–27. • J.M. Gonzalez-Sancho, M. Alvarez-Dolado, A. Munoz, FEBS Lett. (1998) 225–228. • V. Sung, D. Feldman, Mol. Cell. Endocrinol. 164 (2000) 133–143.

  12. 4- inflamation: activation of NFKB pro-inflamatory cytokines (IL-1, IL-8) B.Y. Bao, J. Yao, Y.F. Lee, Carcinogenesis 27 (2006) 1883–1893.

  13. Pre-clinical studies SUPPORT it.

  14. What about the clinical side..??!!

  15. Clinical side • 1- epidemiological studies. • 2- clinical trials.

  16. Epidemiological studies: • Retrospective case-control studies. • Prospective cohort studies.

  17. S. Mocellin, Vitamin D and cancer: Deciphering the truth, Biochim. Biophys. Acta (2011), doi:10.1016/ j.bbcan.2011.07.001

  18. Clinical trials • cancer outcomes. • cancer prevention.

  19. Studies targeting cancer outcomes : • -T.M. Beer, C.W. Ryan, P.M. Venner, D.P. Petrylak, G.S. Chatta, J.D. Ruether, C.H. 643 Redfern, L. Fehrenbacher, M.N. Saleh, D.M. Waterhouse, M.A. Carducci, D. Vicario, 644 R. Dreicer, C.S. Higano, F.R. Ahmann, K.N. Chi, W.D. Henner, A. Arroyo, F.W. Clow, J.645 Clin. Oncol. 25 (2007) 669–674. • S. Attia, J. Eickhoff, G. Wilding, D. McNeel, J. Blank, H. Ahuja, A. Jumonville, M. Eastman, D. Shevrin, M. Glode, D. Alberti, M.J. Staab, D. Horvath, J. Straus, R. 648 Marnocha, G. Liu, Clin. Cancer Res. 14 (2008) 2437–2443. • M.K. Chadha, L. Tian, T. Mashtare, V. Payne, C. Silliman, E. Levine, M. Wong, C. Johnson, D.L. Trump, Cancer 116 (2010) 2132–2139.

  20. Studies targeting cancer outcomes : • - J.M. Lappe, D. Travers-Gustafson, K.M. Davies, R.R. Recker, R.P. Heaney, Am. J. Clin. 652 Nutr. 85 (2007) 1586–1591. • R.T. Chlebowski, K.C. Johnson, C. Kooperberg, M. Pettinger, J. Wactawski- Wende, T. Rohan, J. Rossouw, D. Lane, M.J. O'Sullivan, S. Yasmeen, R.A. Hiatt, J.M.655 Shikany, M. Vitolins, J. Khandekar, F.A. Hubbell, J. Natl. Cancer Inst. 100 (2008) 656 1581–1591. • J. Wactawski-Wende, J.M. Kotchen, G.L. Anderson, A.R. Assaf, R.L. Brunner, M.J. O'Sullivan, K.L. Margolis, J.K. Ockene, L. Phillips, L. Pottern, R.L. Prentice, J. Robbins, T.E. Rohan, G.E. Sarto, S. Sharma, M.L. Stefanick, L. Van Horn, R.B. Wallace, E. Whitlock, T. Bassford, S.A. Beresford, H.R. Black, D.E. Bonds, R.G. Brzyski, B. Caan, R.T. Chlebowski, B. Cochrane, C. Garland, M. Gass, J. Hays, G. Heiss, S.L. Hendrix, B.V. Howard, J. Hsia, F.A. Hubbell, R.D. Jackson, K.C. Johnson, H. Judd, C.L. Kooperberg, L.H. Kuller, A.Z. LaCroix, D.S. Lane, R.D. Langer, N.L. 664 Lasser, C.E. Lewis, M.C. Limacher, J.E. Manson, N. Engl. J. Med. 354 (2006) 665 684–696. • E.L. Ding, S. Mehta, W.W. Fawzi, E.L. Giovannucci, Int. J. Cancer 122 (2008) 1690–1694. • D.P. Trivedi, R. Doll, K.T. Khaw, BMJ 326 (2003) 469.

  21. Conclusion..

  22. Thank you.

  23. Conclusion..

More Related